{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T16:50:40Z","timestamp":1769532640720,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10147-025-02937-5","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T11:39:02Z","timestamp":1765280342000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical profiles and predictors of symptomatic skeletal events in patients with metastatic castration-resistant prostate cancer receiving denosumab"],"prefix":"10.1007","volume":"31","author":[{"given":"Mana","family":"Nakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-8183","authenticated-orcid":false,"given":"Fumihiko","family":"Urabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Iwatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juria","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Fukuokaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahito","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagenori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Miki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"JIKEI-YAYOI Collaborative Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"issue":"11","key":"2937_CR1","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED (2011) Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 65(11):1180\u20131192","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2937_CR2","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S et al (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825\u2013836","journal-title":"Eur Urol"},{"key":"2937_CR3","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/978-981-13-3681-2_16","volume":"91","author":"TJ Aspray","year":"2019","unstructured":"Aspray TJ, Hill TR (2019) Osteoporosis and the ageing skeleton. Subcell Biochem 91:453\u2013476","journal-title":"Subcell Biochem"},{"issue":"6","key":"2937_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrclinonc.2014.70","volume":"11","author":"BA Gartrell","year":"2014","unstructured":"Gartrell BA, Saad F (2014) Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 11(6):335\u2013345","journal-title":"Nat Rev Clin Oncol"},{"key":"2937_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2016.02.002","volume":"44","author":"F Vignani","year":"2016","unstructured":"Vignani F, Bertaglia V, Buttigliero C et al (2016) Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Cancer Treat Rev 44:61\u201373","journal-title":"Cancer Treat Rev"},{"issue":"19","key":"2937_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458\u20131468","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2937_CR7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1093\/jnci\/djh141","volume":"96","author":"F Saad","year":"2004","unstructured":"Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11):879\u2013882","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2937_CR8","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402\u20131418","journal-title":"J Clin Oncol"},{"key":"2937_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.critrevonc.2019.04.020","volume":"139","author":"A Hussain","year":"2019","unstructured":"Hussain A, Lee RJ, Graff JN et al (2019) The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. Crit Rev Oncol Hematol 139:108\u2013116","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9768","key":"2937_CR10","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377(9768):813\u2013822","journal-title":"Lancet"},{"key":"2937_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.011","author":"B Tombal","year":"2025","unstructured":"Tombal B, Choudhury A, Saad F et al (2025) Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011","journal-title":"Ann Oncol"},{"issue":"1","key":"2937_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.prnil.2024.11.003","volume":"13","author":"F Urabe","year":"2025","unstructured":"Urabe F, Kagawa H, Yanagisawa T et al (2025) Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study. Prostate Int 13(1):41\u201348","journal-title":"Prostate Int"},{"issue":"5","key":"2937_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.urolonc.2025.02.007","volume":"43","author":"F Urabe","year":"2025","unstructured":"Urabe F, Tashiro K, Muramoto K et al (2025) Locations of metastases in and oncological outcomes of patients with metastatic castration-sensitive prostate cancer: real-world data from a multicenter study. Urol Oncol 43(5):336","journal-title":"Urol Oncol"},{"issue":"11","key":"2937_CR14","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/iju.15546","volume":"31","author":"F Urabe","year":"2024","unstructured":"Urabe F, Muramoto K, Yanagisawa T et al (2024) Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: a multicenter study. Int J Urol 31(11):1248\u20131255","journal-title":"Int J Urol"},{"issue":"2","key":"2937_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","volume":"49","author":"JA Ford","year":"2013","unstructured":"Ford JA, Jones R, Elders A et al (2013) Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. Eur J Cancer 49(2):416\u2013430","journal-title":"Eur J Cancer"},{"key":"2937_CR16","doi-asserted-by":"publisher","first-page":"e2400078","DOI":"10.1200\/CCI.24.00078","volume":"8","author":"K Ikegami","year":"2024","unstructured":"Ikegami K, Imai S, Yasumuro O et al (2024) External validation and update of the risk prediction model for denosumab-induced hypocalcemia developed from a hospital-based administrative database. JCO Clin Cancer Inform 8:e2400078","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"2937_CR17","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/1097-0142(19880101)61:1<195::AID-CNCR2820610133>3.0.CO;2-Y","volume":"61","author":"MS Soloway","year":"1988","unstructured":"Soloway MS, Hardeman SW, Hickey D et al (1988) Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1):195\u2013202","journal-title":"Cancer"},{"issue":"1","key":"2937_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317(1):48\u201358","journal-title":"JAMA"},{"issue":"1","key":"2937_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.clgc.2021.10.008","volume":"20","author":"MCP Kuppen","year":"2022","unstructured":"Kuppen MCP, Westgeest HM, van den Eertwegh AJM et al (2022) Symptomatic skeletal events and the use of bone health agents in a real-world treated metastatic castration resistant prostate cancer population: results from the CAPRI-study in the Netherlands. Clin Genitourin Cancer 20(1):43\u201352","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"2937_CR20","first-page":"981","volume":"30","author":"H Miyashita","year":"2022","unstructured":"Miyashita H, Cruz C, Patel V (2022) Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate. Support Care Cancer 30(2):981\u2013984","journal-title":"Support Care Cancer"},{"issue":"6","key":"2937_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjc.6602767","volume":"93","author":"A Berruti","year":"2005","unstructured":"Berruti A, Tucci M, Mosca A et al (2005) Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 93(6):633\u2013638","journal-title":"Br J Cancer"},{"issue":"2","key":"2937_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/1097-0142(20010715)92:2<303::AID-CNCR1323>3.0.CO;2-F","volume":"92","author":"A Bayley","year":"2001","unstructured":"Bayley A, Milosevic M, Blend R et al (2001) A prospective study of factors predicting clinically occult spinal cord compression in patients with metastatic prostate carcinoma. Cancer 92(2):303\u2013310","journal-title":"Cancer"},{"issue":"3","key":"2937_CR23","doi-asserted-by":"publisher","first-page":"e242467","DOI":"10.1001\/jamanetworkopen.2024.2467","volume":"7","author":"W Fukuokaya","year":"2024","unstructured":"Fukuokaya W, Mori K, Urabe F et al (2024) Bone-modifying agents in patients with high-risk metastatic castration-sensitive prostate cancer treated with abiraterone acetate. JAMA Netw Open 7(3):e242467","journal-title":"JAMA Netw Open"},{"key":"2937_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16860","author":"Y Goto","year":"2025","unstructured":"Goto Y, Urabe F, Ogihara Y et al (2025) Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management. BJU Int. https:\/\/doi.org\/10.1111\/bju.16860. (In press)","journal-title":"BJU Int"},{"issue":"15 Suppl","key":"2937_CR25","doi-asserted-by":"publisher","first-page":"tps5095","DOI":"10.1200\/jco.2014.32.15_suppl.tps5095","volume":"32","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Stalder L, Bernhard J et al (2014) Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: a noninferiority phase III trial (SAKK 96\/12, REDUSE). J Clin Oncol 32(15 Suppl):tps5095","journal-title":"J Clin Oncol"},{"key":"2937_CR26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","volume":"142","author":"M Clemons","year":"2021","unstructured":"Clemons M, Ong M, Stober C et al (2021) A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. Eur J Cancer 142:132\u2013140","journal-title":"Eur J Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02937-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02937-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T04:07:45Z","timestamp":1769486865000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02937-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02937-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board approved the study protocol (36\u2013005[12104]).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study registration"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}]}}